M&G PLC Purchases 283,296 Shares of Doximity, Inc. $DOCS

M&G PLC raised its position in Doximity, Inc. (NYSE:DOCS) by 96.4% in the third quarter, Holdings Channel reports. The institutional investor owned 577,196 shares of the company’s stock after purchasing an additional 283,296 shares during the period. M&G PLC’s holdings in Doximity were worth $16,161,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of DOCS. Signaturefd LLC raised its position in shares of Doximity by 10.4% in the third quarter. Signaturefd LLC now owns 4,205 shares of the company’s stock worth $119,000 after acquiring an additional 397 shares during the period. Nisa Investment Advisors LLC boosted its stake in shares of Doximity by 59.9% during the 3rd quarter. Nisa Investment Advisors LLC now owns 1,855 shares of the company’s stock worth $53,000 after acquiring an additional 695 shares in the last quarter. Apella Capital LLC grew its position in shares of Doximity by 1.4% during the 3rd quarter. Apella Capital LLC now owns 59,488 shares of the company’s stock valued at $1,647,000 after acquiring an additional 802 shares during the period. GAMMA Investing LLC grew its position in shares of Doximity by 19.8% during the 3rd quarter. GAMMA Investing LLC now owns 5,834 shares of the company’s stock valued at $165,000 after acquiring an additional 963 shares during the period. Finally, Parallel Advisors LLC grew its position in shares of Doximity by 111.0% during the 1st quarter. Parallel Advisors LLC now owns 2,560 shares of the company’s stock valued at $60,000 after acquiring an additional 1,347 shares during the period. Institutional investors and hedge funds own 87.19% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on DOCS shares. Freedom Capital lowered Doximity from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 8th. Canaccord Genuity Group upped their price target on Doximity from $36.00 to $40.00 and gave the stock a “buy” rating in a report on Friday, November 6th. Evercore set a $35.00 price target on Doximity in a research report on Tuesday, September 29th. Piper Sandler reissued an “overweight” rating and issued a $47.00 price objective (up from $42.00) on shares of Doximity in a report on Friday, August 7th. Finally, Barclays raised their price objective on Doximity from $20.00 to $27.00 and gave the company an “equal weight” rating in a report on Friday, August 21st. Eight investment analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $30.45.

Doximity News Summary

Here are the key news stories impacting Doximity this week:

• Positive Sentiment: Some analysts have raised Doximity’s price targets, including Canaccord Genuity to $40, and Needham reiterated its Buy rating. A recent report also highlighted adoption of Doximity’s AI search products by 16 of the top 20 pharmaceutical companies and 34% year-over-year growth in quarterly active workflow prescribers. Analyst price target report Doximity long-term investor takeaways
• Neutral Sentiment: Director Timothy Cabral sold 10,721 shares for about $375,000. The transaction was made under a pre-arranged Rule 10b5-1 plan, which may make it less informative as a signal about his current outlook. Insider transaction report
• Negative Sentiment: Multiple law firms publicized a securities class action covering shares purchased from August 8, 2024, through May 13, 2026, with a November 16 deadline to seek lead-plaintiff status. The complaint alleges Doximity misled investors about market-share losses, competition and advertising practices, including reliance on lower-engagement formats, as well as revenue and growth trends. These claims have not been proven, but the litigation adds uncertainty and could weigh on sentiment. Class action allegations and deadline Advertising disclosure allegations

Insider Activity at Doximity

In related news, Director Kira Wampler sold 2,000 shares of the company’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $32.89, for a total transaction of $65,780.00. Following the completion of the transaction, the director owned 27,923 shares in the company, valued at $918,387.47. This represents a 6.68% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Siddharth Sitaram sold 2,613 shares of the firm’s stock in a transaction dated Wednesday, October 14th. The shares were sold at an average price of $30.68, for a total transaction of $80,166.84. Following the completion of the transaction, the chief accounting officer directly owned 101,432 shares in the company, valued at $3,111,933.76. This represents a 2.51% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 24,471 shares of company stock worth $761,545 over the last three months. Company insiders own 31.80% of the company’s stock.

Doximity Stock Performance

Shares of NYSE DOCS opened at $32.45 on Wednesday. The firm has a market cap of $5.78 billion, a PE ratio of 45.07, a PEG ratio of 34.25 and a beta of 1.29. The firm has a fifty day moving average of $29.33 and a 200 day moving average of $25.43. Doximity, Inc. has a one year low of $17.15 and a one year high of $54.04.

Doximity (NYSE:DOCS) last posted its quarterly earnings data on Thursday, November 5th. The company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.19 by $0.17. The business had revenue of $174.54 million for the quarter. Doximity had a net margin of 21.12% and a return on equity of 15.80%. The business’s revenue for the quarter was up 3.6% on a year-over-year basis. During the same period in the previous year, the business earned $0.45 earnings per share. On average, equities analysts predict that Doximity, Inc. will post 0.74 EPS for the current fiscal year.

Doximity Company Profile

Doximity, Inc. operates a digital platform designed for medical professionals, including physicians and other clinicians. Its services support professional networking, medical news and research discovery, career development, and communication among healthcare professionals. The company also offers clinical workflow tools, including Doximity Dialer, which enables clinicians to make calls and conduct video visits using a work number, as well as digital fax and document services. Doximity provides marketing and recruitment solutions to healthcare organizations and life sciences companies.